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Background: Cerebral palsy (CP) is a heterogeneous neurodevelopmental disorder associated with intellectual
disability in one-third of cases. Recent findings support Mendelian inheritance in subgroups of patients with the
disease. The purpose of this study was to identify a novel genetic cause of paraplegic CP with intellectual disability
in a consanguineous Pakistani family.
Methods: We performed whole-exome sequencing (WES) in two brothers with CP and intellectual disability. Analysis
of AP4M1 mRNA was performed using quantitative real-time PCR on total RNA from cultured fibroblasts. The brothers
were investigated clinically and by MRI.
Results: We identified a novel homozygous AP4M1 mutation c.194_195delAT, p.Y65Ffs*50 in the affected brothers.
Quantitative RT-PCR analysis showed markedly reduced AP4M1 mRNA levels suggesting partial non-sense mediated
mRNA decay. Several clinical and MRI features were consistent with AP-4 complex deficiency. However, in contrast to
previously reported cases with AP4M1 mutations our patients show an aggressive behavior and a relatively late onset
of disease.
Conclusion: This study shows an AP4M1 mutation associated with aggressive behavior in addition to mild dysmorphic
features, intellectual disability, spastic paraparesis and reduced head circumference. Our findings expand the clinical
spectrum associated with AP-4 complex deficiency and the study illustrates the importance of MRI and WES in the
diagnosis of patients with CP and intellectual disability.
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Cerebral palsy (CP) is a common cause of physical disability
in childhood with an incidence of approximately 0.2-3%
[1,2]. The causes of CP are heterogeneous and specific
underlying causes remain unknown in the majority of
cases. It is noteworthy that neonatal hypoxia, previously
assumed to be a predominant cause of CP, accounts for
no more than 10-20% of cases [3,4]. In line with this, in-
dependent studies have provided evidences for genetic
causes behind CP related disorders. This was suggested* Correspondence: niklas.dahl@igp.uu.se
2Department of Immunology, Genetics and Pathology, Science for Life
Laboratory, Uppsala University, Uppsala 751 08, Sweden
Full list of author information is available at the end of the article
© 2014 Jameel et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.already by an earlier twin-study showing an increased
concordance rate for CP in monozygotic vs. dizygotic
twins [5]. Furthermore, the association of CP with con-
genital malformations supported the hypothesis that
genes may be involved in the disease [6,7]. More recent
studies have confirmed that CP may be inherited as a
Mendelian trait caused by single gene mutations in sub-
groups of patients. The four components of the adaptor
protein 4 (AP-4) complex (reviewed by Moreno-De-Luca
et al. [8]) have been linked to monogenic CP. The AP-4
hetero-tetramer is composed of the AP4B1, AP4M1,
AP4E1 and AP4S1 subunits that are of critical importance
for vesicular transport [9]. Thus, the AP-4 complex is re-
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sorts the AMPA glutamate receptors that are required for
excitatory synaptic neurotransmission of importance dur-
ing brain development [10]. To date, a limited number of
families have been described segregating autosomal reces-
sive CP that is caused by a mutation in either of the
AP4B1, AP4E1, AP4M1 and AP4S1 genes [8,11-15]. The
different mutations presumably cause a disruption of the
AP-4 complex integrity and the affected individuals share
clinical characteristics including intellectual disability,
reduced head circumference, short stature and spastic
di- or paraplegia. Symptoms such as hypotonia and/or
microcephaly may be present at birth or in the neonatal
period but development may be within normal ranges up
to several months. The disease progresses usually within
the first 2 years of age (y.o.a.) with loss of acquired motor
functions, peripheral neuropathy, spasticity and some-
times seizures [14,15].
Here we report on a consanguineous family with two
sons affected by a complex form of CP. The brothers
had an onset at approximately 12 months of age (m.o.a)
and they are homozygous for a novel and truncating
AP4M1 gene mutation associated with markedly reduced
AP4M1 mRNA levels. The clinical features in our pa-
tients bring further information on the variability and




The consanguineous family is of Pakistani origin without
family history of any neurological disease. The healthyFigure 1 Family structure and MRI findings. (A) Pedigree of the consan
genotypes are indicated below the symbols. The AT nucleotides (c.194-195
the two affected brothers. (B) Sagittal T2-weighted MR image of ind. IV:3 sh
upper vermis is slightly hypoplastic/atrophic (black arrow). (C) T1-weighted
containing space around the mesencephalon (*) is enlarged indicating sligparents are first cousins with four children (Figure 1A).
Two sons have cerebral palsy, spastic paraplegia and intel-
lectual disability whereas two sons are healthy. Informed
and written consent was obtained from the parents being
legal guardians of their sons. The study was carried out
in accordance with the Declaration of Helsinki and the
protocol approved by the local ethical committee,
National Institute for Biotechnology and Genetic
Engineering (NIBGE), >Faisalabad, Pakistan.
Whole exome sequencing
Whole exome sequencing (WES) was performed on
50 ng of genomic DNA from the two affected brothers
as described previously [16]. In brief, DNA was sheared
by sonication with the Covaris S2 instrument (Covaris,
Inc.). Fragment libraries were created from the sheared
samples using the AB Library Builder System (Life Tech-
nologies) and target enrichment was performed accord-
ing to the manufacturer’s protocols (Agilent SureSelect
Human All Exon v4 kit). Exome capture was conducted
by hybridizing the DNA libraries with biotinylated RNA
baits for 24 h followed by extraction using streptavidin
coated magnetic beads. Captured DNA was then amplified
followed by emulsion PCR using the EZ Bead System (Life
Technologies) and sequenced on the SOLiD5500xl sys-
tem, generating over 100 million reads of 75 bp length
for each of the samples.
Alignment of reads to the human reference sequence
(hg19 assembly) and variant detection was performed
using v2.1 of the LifeScope Software. SNPs and indel
data was stored in an in-house exome database to-
gether with variant annotation information obtainedguineous family with two affected brothers (filled squares). The AP4M1
) represent the wild-type allele that is deleted (−−) on both alleles in
ows a thin posterior third of the corpus callosum (white arrow). The
transverse image displays very wide temporal horns (arrow). The liquor
ht dimensions of the brain stem and medial temporal lobes.
Table 1 Clinical features of patients with AP4M1
mutations in this and previous studies







Gender M M 3F/2M 3F/1M
Age at last
examination (y.)
14 12 1.5/21/22/23/24 2.5/10.5/11/17
Head circumference −2SD −2SD −1 to −2.5 SD −2 to −4 SD
Height (cm) 157 137 NA NA
Intellectual disability Severe Severe Severe in 5/5 Severe in 3/4
Seizures + - - +
Shy character - - + +
Aggressive behavior + + - -
Stereotype laughter - - + +
Severe speech
disorder
+ + + +
Infantile hypotonia + + + +
Hypertonia + + + +
Hyperreflexia + + NA NA
Babinski sign + + + NA
Spasticity + + + +
Club feet - - + +
Independent
walking (y.)
2 4 - +/−
Ambulation - - - -
Craniofacial features
Facial hypotonia - - NA +
Bitemporal narrowing - - NA +
Broad nasal bridge - - NA +
Bulbous nose - + NA +
Short philtrum + + NA +










Abbreviations: + present, − absent, SD standard deviation, M male, F female,
NA: no data available, CC: corpus callosum, y.: years.
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were used to identify potentially damaging variants that
were shared between the patients while not present in
any of the other ~800 exomes in the in-house database.
PCR and mRNA analysis
Segregation analysis of the AP4M1 variant c.194_195delAT,
p.Y65Ffs*50 was performed by PCR and Sanger sequen-
cing using standard protocols. Total RNA was extracted
from cultured fibroblasts of two patients and two control
individuals using the PureLink RNA Mini kit (Invitrogen),
treated with DNA-free (Ambion) and then converted into
cDNA by using RevertAid H Minus First Strand cDNA
Synthesis Kit (Fermentas). Quantitative real-time PCR was
performed with the Platinum SYBR Green qPCR SuperMix-
UDG kit (Invitrogen) then run and analyzed on the
MxPro Real-Time PCR System (Stratagene). The primers
for AP4M1 mRNA quantification were designed to amp-
lify exon-intron boundaries between exons 2 and 4, re-
spectively, to ensure that the amplicons were cDNA
specific. All reactions were performed three times and in
triplicates and normalized to β-actin mRNA. Student’s
two-tailed t-test was used for statistical analysis. Sanger se-
quencing was performed on the cDNA amplicon contain-
ing exon 3 in order to confirm the mutation. Primers
sequences used to amplify the AP4M1 cDNA and AP4M1
exon 3 on genomic DNA were designed using Primer 3
Plus software (primer3plus.com/). All primer sequences
are available upon request.
Results
Clinical investigation
Pregnancies and deliveries of both children were normal.
Head circumference and muscle tonus were within normal
ranges after delivery and during the first months of age.
Hypotonia became evident in the elder brother (Ind. IV:3)
at approximately 12 m.o.a and he learned to walk without
support at 2 years of age. Spasticity developed gradually in
the lower limbs with contractures of feet and positive
Babinski sign. The ability to walk was lost at 6 years of
age. Speech remained limited to a few single words and
severe intellectual disability was evident at 3 years of age.
He learned simple purposeful hand movements and he
can feed himself. Seizures developed in childhood as well
as an aggressive behavior in response to minor stimuli.
Head circumference was -2SD at 14 years of age and facial
dysmorphisms was otherwise restricted to a short phil-
trum (Table 1). MRI investigation, performed with a
0.23 T system at age 14 years of age showed a thin pos-
terior corpus callosum, an enlarged third ventricle and
widened temporal horns of the lateral ventricles. The mes-
encephalon and pons were thinner than expected for age.
The upper vermis was hypoplastic/atrophic (Figure 1B-C).
No abnormality in signal intensity was found.The second affected brother (ind. IV:4) was diagnosed
with hypotonia at 12 months of age. Spasticity developed
gradually in the lower limbs with contractures of feet
and Babinski sign (Table 1). He learned to walk at 4 years
of age but this ability was lost at 6 years of age. As for
the elder brother, a severe cognitive deficit was evident
with speech limited to a few single words, simple pur-
poseful hand movement and aggressive behavior. Head
circumference was -2SD at 12 years of age. Dysmorphic
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The patient was not available for MRI investigation.
The upper limbs were unaffected in both brothers and
none of them had pseudobulbar signs, impaired vision or
hearing. Both brothers had a normal height, i.e. 157 cm and
137 cm at 14 years of age and 12 years of age, respectively.
Whole exome sequencing
Whole exome enrichment was performed on DNA sam-
ples from the two affected family members (ind. IV:3 and
IV:4). After exome capture, the enriched DNA was se-
quenced using the Ion Proton system (Life technologies)
and sequences were aligned to the human reference gen-
ome (hg19). An average of 97% of the exonic baits were
covered at least 1x, and 90% were covered >10x. Common
variants were excluded by filtering against dbSNP130
(MAF >0.01) and 800 in house exome. Using filtered WES
data from the two brothers, we identified altogether nine
novel candidate variants. Five missense variants were lo-
cated in the X-chromosome genes FANCB, CCNB3,
RGAG1, GPR50 and HAUS7, respectively. However, none
of the amino acid substitutions were predicted as patho-
genic and the five genes were not previously associated
with the clinical features observed in our patients. Four
autosomal and homozygous variants were identified in the
TNFRSF14, AP4M1, RGMA and NINL genes. One of
these variants is located in exon 3 of the AP4M1 gene
(NM_004722.3) and consists of a two base pair deletion
c.194_195delAT resulting in a frameshift p.Y65Ffs*50.
With the previous knowledge on phenotypes associated
with AP4M1 we performed Sanger sequencing and con-
firmed homozygosity for the AP4M1 deletion in the two
affected family members. The unaffected parents and one
healthy brother were heterozygous for the wild-type allele
(Figure 2A). The eldest and healthy brother was not avail-
able for sampling. Furthermore, the two base pair deletion
was excluded in 200 Swedish and 200 Pakistani control
chromosomes and it was not present in AP4M1 sequences
from 800 in house exomes, the dbSNP (www.ncbi.nlm.
nih.gov/SNP/) or the EVS data release (ESP6500SI-V2)
on the Exome Variant Server, NHLBI GO Exome Se-
quencing Project (ESP), Seattle, WA (URL: http://evs.gs.
washington.edu/EVS/) when accessed March 2014. The
variant c.194_195delAT is located in the region encod-
ing a highly conserved longin-like domain (Figure 2B).
Longin domains are globular structures found in differ-
ent protein families that mediate protein-protein inter-
actions in the membrane trafficking machinery [18].
mRNA analysis
To investigate the effect of the c.194_195delAT mutation
at the transcript level we first sequenced the AP4M1
cDNA amplicon spanning exon 3 from both brothers
and we detected only the mutated transcript. We thenquantified the AP4M1 mRNA from cultured fibroblasts
of the two affected family members (ind. IV:3 and ind.
IV:4) as well as from control individuals using real-time
qRT-PCR. The results indicated a 3-fold reduction in
AP4M1 mRNA expression in patient derived fibroblasts
when compared to matched control fibroblasts (p < 0.0026,
Figure 2C). The relative expression of AP4M1 in cases with
respect to controls where calculated after normalization
to β-actin.
Discussion
The phenotype in the two affected brothers of our family
manifests as diplegic CP and severe intellectual disabil-
ity. Autosomal recessive inheritance was likely because
of the consanguineous and healthy parents. X-linked in-
heritance was possible but became highly unlikely when
combining the results from bioinformatic analysis of
X-chromosome variants with the clinical observations.
Instead, a search for homozygous variants in our WES
data revealed four autosomal genes including the AP4M1
gene that is known to be associated with features observed
in our patients. The AP4M1 mutation c.194_195delAT
mutation results in a frame-shift and a premature stop p.
Y65Ffs*50. Further analysis of the AP4M1 transcript in
our patients showed that the deletion is associated with a
three-fold reduction in AP4M1 mRNA levels presumably
because of incomplete non-sense mediated mRNA decay
[19,20]. The frame-shift mutation is positioned within a
region encoding the highly conserved longin-like domain
located in the more N-terminal part of the protein. Longin
domains are found in several protein families and serves
as important regulators of membrane trafficking via pro-
tein–protein and intramolecular binding specificities [18].
Consequently, any translation of AP4M1 c.194_195delAT
mRNA predicts a protein with a loss of membrane traf-
ficking properties as well as a complete loss of a functional
C-terminal cargo-binding domain [21]. Thus, the trun-
cated AP4M1 protein would most likely be non-functional
even if integrated in the AP-4 complex and with a result-
ing loss of complex integrity. In combination, the previous
reports on AP-4 complex deficiency together with our
genetic and clinical findings made the AP4M1 mutation
a likely cause of the disease.
Our patients share several clinical features with other
AP-4 deficient cases such as intellectual disability, reduced
head circumference, spasticity and facial dysmorphisms,
including a short philtrum and a bulbous nose [14]. Fur-
thermore, the one individual available for MRI showed en-
larged lateral ventricles and a thin corpus callosum that
are typical findings reported previously in a few cases with
mutations in each of the AP4B1, AP4M1 and AP4E1
genes, respectively [8,11-15]. In these previously reported
patients signs of brain hypoplasia or atrophy are frequent
but variable. Noteworthy, some clinical features in our
Figure 2 Gene and expression analysis. (A) Sequence chromatograms showing part of the AP4M1 exon 3 (NM_004722.3) obtained from a
healthy control (top), a heterozygous parent (middle) and the affected individual IV:3 (bottom). The two nucleotides in AP4M1 (c.194_195delAT, p.
Y65Ffs*50) deleted on the mutated allele are indicated by asterisks in the top panel. The arrow denotes a synonymous SNP (rs367614875) in the
middle panel. Codons corresponding to the two alleles are indicated with the altered reading frame in the bottom chromatogram. (B) Schematic
representation of the AP4M1 protein with its functional domains (http://www.ebi.ac.uk/interpro/protein/O00189) and all reported mutations (top).
The degree of conservation of the Tyr65 residue (shaded) is shown across different species (bottom). (C) Quantitative RT-PCR of AP4M1 mRNA
expression in fibroblasts cells from cases (n = 2) and healthy controls (n = 2). Data are normalized to β-actin mRNA and presented as cases relative
to controls ± standard deviation. The relative expression of AP4M1 in controls is set to one. The AP4M1 expression levels in patients are reduced
three-fold when compared to controls (P = 0.0026, two sided Student’s t-test assuming equal variance).
Jameel et al. BMC Medical Genetics 2014, 15:133 Page 5 of 7
http://www.biomedcentral.com/1471-2350/15/133patients were different when compared to the few previ-
ously reported cases with mutations in the AP-4 subunit
genes [8,11-15]. The clinical onset was relatively late, the
body heights were within normal ranges for age and the
upper limb functions were retained. Furthermore, the
brothers have an aggressive behavior in response to minor
stimuli in contrast to other patients with AP-4 deficiency.
The reason for the clinical variation among CP patients
carrying different mutations in AP4B1, AP4M1, AP4E1and AP4S1 is unclear. It has been shown that the loss
or structural change of a single AP-4 subunit disrupts
the integrity of the entire AP-4 complex. Consequently,
mutations in any of the AP-4 subunits would presumably
have the same effects on vesicular glutamate receptor
transport and neurotransmission resulting in similar clin-
ical presentations. Therefore, one possible explanation for
the clinical variability between individuals with mutations
in genes encoding different AP-4 subunits is the effect
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ported when comparing our observations with the two
previously described families with truncating mutations
in the AP4M1 subunit gene [14,15].
Still, the AP-4 complex deficiency highlights two im-
portant aspects: It unravels a subgroup of patients with
CP inherited as a Mendelian trait that can be recognized
by a combination of appropriate diagnostic tools includ-
ing WES. Second, AP-4 deficiency illustrates how a per-
turbed mechanism caused by interacting factors results
in a clinical entity with CP and intellectual disability. In
line with this, other factors and proteins involved in the
AP-4 mediated vesicular trafficking may become strong
candidates in the etiology of CP.
Conclusions
We used whole-exome sequencing and identified a novel
and truncating AP4M1 mutation in two brothers with
cerebral palsy and intellectual disability. Reduced levels of
AP4M1 mRNA in the patients suggest incomplete non-
sense mediated decay. The clinical investigation revealed
aggressive behavior, normal body height, retained upper
limb function and relatively late onset that add to the clin-
ical variability in AP-4 deficiency. Still, the combination of
hypotonia in infancy, minor facial dysmorphisms, reduced
head circumference or microcephaly, para- or tetraplegia,
severe intellectual disability and typical MRI findings
should make AP-4 deficiency a conceivable diagnosis. Our
study provides additional support for autosomal recessive
inheritance in a subgroup of patients with CP and intellec-
tual disability. Further studies are now needed to establish
the frequency of AP-4 mutations and their variable clinical
outcome.
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